Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
67 hedge funds and large institutions have $157M invested in Adamas Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 14 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
22% more call options, than puts
Call options by funds: $912K | Put options by funds: $745K
8% more capital invested
Capital invested by funds: $146M → $157M (+$11.6M)
8% less funds holding
Funds holding: 73 → 67 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.7M |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$2.81M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.48M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.16M |
| 5 |
Two Sigma Investments
New York
|
+$780K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$10.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.75M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.44M |
| 4 |
Morgan Stanley
New York
|
-$1.37M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.29M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
California Public Employees Retirement System
Sacramento,
California
| – | -$77K | -16,100 | Closed |
|
77
Creative Planning
Overland Park,
Kansas
| – | -$48K | -10,000 | Closed |
|
|
PCM
78
Pinz Capital Management
New York
| – | -$23K | -4,850 | Closed |
|
|
QT
79
Quantbot Technologies
New York
| – | -$21K | -4,543 | Closed |
|
80
Simplex Trading
Chicago,
Illinois
| – | -$16.7K | -3,236 | Closed |
|
ADMS Hedge Fund Activity: Q2 2021 in Review
67 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2021, worth a combined $157M — up 8% from $146M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ADMS and 8 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 24 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $11.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $10.6M sold.
- 67 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2021, down from 73 in Q1 2021.
- Funds reported $157M of Adamas Pharmaceuticals stock for Q2 2021, up 8% quarter-over-quarter.
- 8 funds opened new Adamas Pharmaceuticals positions in Q2 2021 and 14 closed out, a net change of -6 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2021 was Point72 Asset Management, an estimated $11.7M added.
- The largest Adamas Pharmaceuticals seller in Q2 2021 was Avidity Partners Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2021.